News

The drug will now be promoted solely by Salix Pharmaceuticals, whilst Altana concentrates its efforts in the field of respiratory therapeutics. Mr George Cole, president, Altana Pharma US

The FDA previously granted fast track status to the overall Ancrod development program for acute ischemic stroke and now has additionally confirmed fast track status for this clinical

The phase I trial is administering AL-208 to 48 healthy adults randomized into six dose groups to evaluate safety, tolerability and pharmacokinetics. Allon expects that the study will

The primary objective of the phase II trial is to determine the efficacy of the investigational agent in terms of tumor response rate in patients with advanced bronchioloalveolar

This breakthrough could dramatically speed up the discovery of improved treatments for conditions such as diabetes, Alzheimer’s disease, Parkinson’s disease, stroke, and spinal cord injury. In laboratory experiments,

In 1999, Fibrillex received US orphan drug designation, which will give the product seven years of market exclusivity upon FDA approval. Neurochem plans to complete the submission of

The drug has previously been studied by Oxis International in an indication to treat ulcerative colitis. Because phase I safety studies were performed by Oxis during these trials,

Acute coronary syndrome (ACS) occurs when an atherosclerotic plaque ruptures in a coronary artery, which triggers the coagulation cascade resulting in the formation of a blood clot. The

The study was conducted in order to address concerns raised by the FDA regarding the safety and efficacy of the drug. In a written response to the company’s